We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Progyny (PGNY) Soars to 52-Week High, Time to Cash Out?
Read MoreHide Full Article
Shares of Progyny (PGNY - Free Report) have been strong performers lately, with the stock up 6.5% over the past month. The stock hit a new 52-week high of $68.32 in the previous session. Progyny has gained 48.3% since the start of the year compared to the -3.6% move for the Zacks Medical sector and the -39% return for the Zacks Medical Services industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 4, 2021, Progyny reported EPS of $0.17 versus consensus estimate of $0.07.
For the current fiscal year, Progyny is expected to post earnings of $0.5 per share on $513.76 million in revenues. This represents a 177.78% change in EPS on a 48.98% change in revenues. For the next fiscal year, the company is expected to earn $0.59 per share on $768.27 million in revenues. This represents a year-over-year change of 17.33% and 49.54%, respectively.
Valuation Metrics
Progyny may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Progyny has a Value Score of F. The stock's Growth and Momentum Scores are A and B, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 125.7X current fiscal year EPS estimates. On a trailing cash flow basis, the stock currently trades at 276.3X versus its peer group's average of 23X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Progyny currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Progyny passes the test. Thus, it seems as though Progyny shares could still be poised for more gains ahead.
How Does Progyny Stack Up to the Competition?
Shares of Progyny have been rising, and the company still appears to be a decent choice, but what about the rest of the industry? Some of its industry peers are also solid potential picks, including Premier (PINC - Free Report) , AMN Healthcare Services (AMN - Free Report) , and bioMerieux (BMXMF - Free Report) , all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices.
However, it is worth noting that the Zacks Industry Rank for this group is in the bottom half of the ranking, so it isn't all good news for Progyny. Still, the fundamentals for Progyny are promising, and it still has potential despite being at a 52-week high.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Progyny (PGNY) Soars to 52-Week High, Time to Cash Out?
Shares of Progyny (PGNY - Free Report) have been strong performers lately, with the stock up 6.5% over the past month. The stock hit a new 52-week high of $68.32 in the previous session. Progyny has gained 48.3% since the start of the year compared to the -3.6% move for the Zacks Medical sector and the -39% return for the Zacks Medical Services industry.
What's Driving the Outperformance?
The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 4, 2021, Progyny reported EPS of $0.17 versus consensus estimate of $0.07.
For the current fiscal year, Progyny is expected to post earnings of $0.5 per share on $513.76 million in revenues. This represents a 177.78% change in EPS on a 48.98% change in revenues. For the next fiscal year, the company is expected to earn $0.59 per share on $768.27 million in revenues. This represents a year-over-year change of 17.33% and 49.54%, respectively.
Valuation Metrics
Progyny may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Progyny has a Value Score of F. The stock's Growth and Momentum Scores are A and B, respectively, giving the company a VGM Score of B.
In terms of its value breakdown, the stock currently trades at 125.7X current fiscal year EPS estimates. On a trailing cash flow basis, the stock currently trades at 276.3X versus its peer group's average of 23X. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks Rank
We also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Progyny currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Progyny passes the test. Thus, it seems as though Progyny shares could still be poised for more gains ahead.
How Does Progyny Stack Up to the Competition?
Shares of Progyny have been rising, and the company still appears to be a decent choice, but what about the rest of the industry? Some of its industry peers are also solid potential picks, including Premier (PINC - Free Report) , AMN Healthcare Services (AMN - Free Report) , and bioMerieux (BMXMF - Free Report) , all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices.
However, it is worth noting that the Zacks Industry Rank for this group is in the bottom half of the ranking, so it isn't all good news for Progyny. Still, the fundamentals for Progyny are promising, and it still has potential despite being at a 52-week high.